Menomune (meningococcal polysaccharide vaccine) discontinuation
Sanofi Pasteur, the manufacturer of meningococcal polysaccharide vaccine (Menomune), announced in February 2017 that it is discontinuing production of the vaccine. The company expects to be able to ship orders to providers until mid-2017. The remaining lots will expire in June or in September 2017, according to Sanofi Pasteur. The company advises that providers with questions about this discontinuation should contact Sanofi Pasteur Customer Account Management at 1-800-822-2463.
With the discontinuation of Menomune, no meningococcal polysaccharide vaccines licensed for use in people 56 years of age are available in the United States. People in this age group who need a meningococcal vaccine, such as travelers to the “meningitis belt” (map) in Africa or pilgrims to the Hajj in Saudi Arabia, should receive a quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) instead.
- Page created: March 24, 2017
- Page last updated: March 24, 2017
- Page last reviewed: March 24, 2017
- Content source: